US Stock MarketDetailed Quotes

GSK GlaxoSmithKline

Watchlist
  • 40.260
  • +0.240+0.60%
Close Aug 9 16:00 ET
  • 40.260
  • 0.0000.00%
Post 20:01 ET
82.11BMarket Cap16.18P/E (TTM)

GlaxoSmithKline Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

GlaxoSmithKline Earnings Date

Currency: GBP

Period

Q2 FY2024 Earnings

Jul 31, 2024

Revenue(YoY)

7.88B

+9.84%
EPS(YoY)

0.57

-10.26%
Analyst Rating

Buy

Aug 7, 2024

GlaxoSmithKline Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 7 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: GBP

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 8.004B--
--2024/Q3-- / 8.405B--
Jul 31, 20242024/Q27.884B / 7.493B--
May 1, 20242024/Q17.363B / 7.060B--
--2023/Q48.052B / 7.621B--
DatePeriodRevenue/EstimateEarnings Call
--2024/Q4-- / 8.004B--
--2024/Q3-- / 8.405B--
Jul 31, 20242024/Q27.884B / 7.493B--
May 1, 20242024/Q17.363B / 7.060B--
--2023/Q48.052B / 7.621B--

Unlock Free Earnings Estimates

GlaxoSmithKline Earnings Reports

  • 6-K: Gsk Delivers Continued Strong Performance and Upgrades 2024 Guidance

    Jul 31 12:31 ET

  • 6-K: Gsk Makes a Strong Start to 2024 with Improving Outlook for the Year

    May 1 12:34 ET

  • GlaxoSmithKline | 6-K: Glaxosmithkline 2023 Annual Report on Form 20-F

    Mar 5 13:13 ET

  • GlaxoSmithKline | 20-F: FY2023 Annual Report

    Mar 5 12:18 ET

    • Read more

    Analysis

    Analyst Rating

    Updated: Aug 7, 2024

    Buy

    • Buy

      66.67%

    • Hold

      16.67%

    • Sell

      16.67%

    Price Target

    No Data

    Heat List
    US
    Overall
    Symbol
    Latest Price
    % Chg
    Concept CAR-T Therapy
    CAR-T Therapy
    Intraday-0.15%